8-K: Rafael Holdings Submits NDA for NPC Drug, Reports Financials

Rafael Holdings announced the submission of a New Drug Application (NDA) for remibetadex to treat Niemann-Pick Disease Type C, alongside its fiscal year-end financial results showing a reduced net loss.

Summary

• Rafael Holdings, Inc. reported its financial results for the fiscal year ended July 31, 2026, and announced a significant corporate update regarding its subsidiary, Cyclo Therapeutics, LLC.
• Cyclo Therapeutics submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for remibetadex (Trappsol Cyclo) for the treatment of Niemann-Pick Disease Type C (NPC).
• The NDA submission is supported by the Phase 3 TransportNPC study, earlier clinical data, and an overall survival analysis.
• The Phase 3 TransportNPC study did not meet its primary endpoint in the overall population (p=0.19) but showed a 71% slowing of disease progression in a prespecified analysis of patients on background therapy (p=0.046).
• Remibetadex demonstrated an 85% reduction in the risk of mortality in infantile-onset NPC patients compared to registry controls (p=0.044).
• The company reported a net loss attributable to Rafael Holdings of $29.6 million, or $0.58 per share, for the full fiscal year 2026, an improvement from $30.5 million, or $1.04 per share, in the prior year.
• Cash and cash equivalents stood at $22.1 million as of July 31, 2026.
• The company also noted the USAN Council assigned the nonproprietary name remibetadex to the compound.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed to slightly positive development, primarily driven by the significant regulatory milestone of an NDA submission, but tempered by the mixed results of the Phase 3 trial and the company's ongoing financial challenges.

Positives

• Submission of a New Drug Application (NDA) to the FDA for remibetadex for the treatment of Niemann-Pick Disease Type C (NPC).
• Remibetadex has received Orphan Drug, Fast Track, and Rare Pediatric Disease designations from the FDA.
• A prespecified analysis of the Phase 3 TransportNPC study showed a 71% slowing of disease progression in patients receiving background therapy (p=0.046).
• An overall survival analysis showed an 85% reduction in the risk of mortality in infantile-onset NPC patients compared to matched registry controls (p=0.044).
• The net loss attributable to Rafael Holdings decreased to $29.6 million for fiscal year 2026 from $30.5 million in fiscal year 2025.
• General and administrative expenses decreased significantly in both the fourth quarter and full fiscal year 2026 compared to the prior year.
• The company is eligible for a Rare Pediatric Disease Priority Review Voucher upon approval, which could provide non-dilutive capital.

Negatives

• The Phase 3 TransportNPC study did not meet its primary endpoint in the overall population (p=0.19).
• Serious adverse events occurred more frequently with remibetadex than with placebo in the Phase 3 study (35.9% vs. 16.7%).
• The company reported a net loss of $29.6 million for fiscal year 2026.
• Cash and cash equivalents decreased to $22.1 million as of July 31, 2026, from $52.8 million in the prior year.
• The company has a substantial doubt about its ability to continue as a going concern, as noted in the forward-looking statements.

Risks

• The FDA may not accept for filing or approve the NDA for remibetadex based on the available data, particularly given the Phase 3 study did not meet its primary endpoint in the overall population.
• The company has a substantial doubt about its ability to continue as a going concern.
• The risk that the company may not receive or be able to monetize a Priority Review Voucher.
• Potential for serious adverse events occurring more frequently with remibetadex than placebo.
• The need for additional financing.

Future Outlook

The company is preparing for a potential commercial launch of remibetadex pending FDA approval and is awaiting the FDA's determination on filing and potential Priority Review for the NDA. The company also holds interests in other clinical-stage and early-stage pharmaceutical development companies and an orthopedic-focused medical device company.

Management Comments

• "This submission is an important milestone for Rafael Holdings and, most importantly, for patients living with NPC," said Howard Jonas, Chairman and Chief Executive Officer of Rafael Holdings.
• "I believe the totality of the data, including the Phase 3 trial results and the overall survival analysis, supports the potential of remibetadex for patients with limited treatment options."
• "Pending FDA approval, we are excited to bring remibetadex to patients and families who urgently need new options to treat NPC."
• "With the data in the NDA and Orphan Drug, Fast Track and Rare Pediatric Disease designations in place, upon the FDAs filing of the NDA, we believe remibetadex is well positioned for review, and an approval would make it eligible for a Priority Review Voucher, a potential source of non-dilutive capital."
• "With this important milestone completed, we are preparing for a potential commercial launch, and we look forward to working with the FDA as the regulatory review process advances."
• "We are grateful to the investigators, patients, families and advocates who made this milestone possible."
• "Remibetadex was generally well tolerated, with no new safety signals observed, although serious adverse events occurred more frequently with remibetadex than with placebo (35.9% vs. 16.7%)."

Industry Context

StockSavvy.ai notes that the submission of an NDA for a rare disease treatment is a significant event in the biotechnology sector. The mixed results of the Phase 3 trial, while concerning, are not uncommon in rare disease drug development, where smaller patient populations can lead to statistical challenges. The company's focus on a rare, fatal genetic disorder aligns with industry trends towards developing treatments for unmet medical needs. The potential for a Priority Review Voucher is a recognized mechanism to incentivize development in this area.

Related Party Transactions

• Due to related parties, net was $355,000 as of July 31, 2026, compared to $723,000 as of July 31, 2025.

Stakeholder Impact

• Shareholders: The NDA submission is a key value driver, but the mixed trial results and financial situation present risks. The potential for a Priority Review Voucher could be a positive catalyst.
• Patients with NPC: The NDA submission offers hope for a new treatment option for a rare, fatal disease.
• Creditors: The company's substantial doubt about its ability to continue as a going concern may raise concerns about its long-term viability.

Next Steps

• The FDA will determine within 60 days whether the NDA for remibetadex is filed.
• If filed, the FDA will determine if Priority Review will be granted.
• The FDA will assign a PDUFA target action date if the NDA is filed.
• Preparation for a potential commercial launch of remibetadex.
• Continued development of other clinical-stage and early-stage pharmaceutical candidates and medical devices.

Key Dates

Recommendation

The hold recommendation is based on the significant regulatory milestone of the NDA submission for remibetadex, which addresses a critical unmet need. However, this is balanced by the mixed Phase 3 trial results (failure to meet primary endpoint in overall population), the occurrence of more serious adverse events, and the company's precarious financial position, including the 'substantial doubt about its ability to continue as a going concern.' While the potential for a Priority Review Voucher offers a path to non-dilutive capital, the FDA's ultimate decision on the NDA remains a significant uncertainty. Investors should await further clarity on the FDA review process and the company's ability to secure necessary funding.

Keywords

Niemann-Pick Disease Type C, Remibetadex, Trappsol Cyclo, NDA Submission, FDA, Biotechnology, Rare Disease, Clinical Trial